

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

SK-N-AS

RRID:CVCL_1700

Type: Cell Line

Proper Citation

RRID:CVCL_1700

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1700

Proper Citation: RRID:CVCL_1700

Description: Cell line SK-N-AS is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Neuroblastoma

Defining Citation: [PMID:2987426](#), [PMID:6610792](#), [PMID:7838528](#), [PMID:9283597](#), [PMID:11550280](#), [PMID:12068308](#), [PMID:12702577](#), [PMID:15892104](#), [PMID:16822308](#), [PMID:17506115](#), [PMID:18082704](#), [PMID:18534018](#), [PMID:18724359](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20655465](#), [PMID:22213050](#), [PMID:22460905](#), [PMID:23202128](#), [PMID:24466371](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28192521](#), [PMID:28350380](#), [PMID:30459281](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:33921066](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SK-N-AS

Synonyms: SKN-AS, SKNAS

Cross References: BTO:BTO_0002827, CLO:CLO_0009051, EFO:EFO_0002859, CLDB:cl4330, CLDB:cl4331, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610,

ArrayExpress:E-MTAB-6654, ATCC:CRL-2137, BioGRID_ORCS_Cell_line:376, BioSample:SAMN03473210, BioSample:SAMN10987940, cancercellines:CVCL_1700, Cell_Model_Passport:SIDM01101, CGH-DB:61-1, CGH-DB:9098-4, ChEMBL-Cells:ChEMBL3308785, ChEMBL-Targets:ChEMBL1075578, CLS:305272, Cosmic:724828, Cosmic:848935, Cosmic:930074, Cosmic:1019941, Cosmic:1109104, Cosmic:1162002, Cosmic:1167418, Cosmic:1518070, Cosmic:1526646, Cosmic:1543772, Cosmic:2058112, Cosmic:2239472, Cosmic:2393642, Cosmic:2485950, Cosmic-CLP:724828, DepMap:ACH-000260, ECACC:94092302, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:724828, GEO:GSM563352, GEO:GSM692855, GEO:GSM887592, GEO:GSM888675, GEO:GSM1670449, GEO:GSM2371254, GEO:GSM2394379, GEO:GSM4104591, GEO:GSM4104592, GEO:GSM4104635, GEO:GSM4104636, GEO:GSM4105338, GEO:GSM4105339, GEO:GSM4105340, GEO:GSM4105341, GEO:GSM4105342, IARC_TP53:23597, ICLC:HTL95026, IGRhCellID:SKNAS, LiGeA:CCLE_394, LINCS_LDP:LCL-1969, Lonza:447, Lonza:1617, MetaboLights:MTBLS541, PharmacDB:SKNAS_1404_2019, PRIDE:PXD010745, PRIDE:PXD011187, PRIDE:PXD023088, PRIDE:PXD024551, PRIDE:PXD030304, Progenetix:CVCL_1700, PubChem_Cell_line:CVCL_1700, Wikidata:Q54954411

ID: CVCL_1700

Record Creation Time: 20220427T221547+0000

Record Last Update: 20260829T235933+0000

Ratings and Alerts

No rating or validation information has been found for SK-N-AS.

No alerts have been found for SK-N-AS.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 570 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

García-Vioque V, et al. (2026) Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas. *Molecular biomedicine*, 7(1).

Schober AS, et al. (2026) USP29-regulated noncanonical stabilization of the hypoxia-inducible factor-? in aggressive prostate cancer. *Molecular oncology*.

Norouzi M, et al. (2026) DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. *Cancer letters*, 646, 218383.

Guyot C, et al. (2026) IL4i1 activity generates oncometabolites that rescue neuroblastoma cells from oxidative death. *Cell reports*, 45(6), 117441.

Pece A, et al. (2026) Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. *Molecular oncology*, 20(3), 823.

Ludwig M, et al. (2026) YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. *Cancers*, 18(3).

Xu A, et al. (2026) Acyltransferase ZDHHC22 promotes N-Myc transcriptional activation to drive neuroblastoma progression and chemoresistance. *Molecular cell*, 86(10), 1945.

Giudice AM, et al. (2025) D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5276.

Treis D, et al. (2025) Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. *Cell death & disease*, 16(1), 318.

Hollander JF, et al. (2025) Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. *Cancer research communications*, 5(1), 167.

Nguyen TT, et al. (2025) The mevalonate pathway couples lipid metabolism to amino acid synthesis via ubiquinone-dependent redox control. *bioRxiv : the preprint server for biology*.

Jiang L, et al. (2024) B7-H3-Targeted CAR-V γ 1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors. *Cancer research*, 84(23), 4066.

Bate-Eya LT, et al. (2024) Sustained cancer-relevant alternative RNA splicing events driven by PRMT5 in high-risk neuroblastoma. *Molecular oncology*.

Abu-Zaid A, et al. (2024) Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma. *Cell reports. Medicine*, 5(3), 101468.

Mazar J, et al. (2024) The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner. *Cancer research communications*, 4(1), 65.

Mengzhen Z, et al. (2024) Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma. *Journal of cancer research and clinical oncology*, 150(3), 109.

Zaghmi A, et al. (2024) High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance. *Molecular oncology*, 18(2), 317.

Volegova MP, et al. (2024) The MYCN 5' UTR as a therapeutic target in neuroblastoma. *Cell reports*, 43(5), 114134.

Aljouada NA, et al. (2024) Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity. *Molecular oncology*.

Gupta A, et al. (2024) DKC1-mediated pseudouridylation of rRNA targets hnRNP A1 to sustain IRES-dependent translation and ATF4-driven metabolic adaptation. *bioRxiv : the preprint server for biology*.